These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 32934884)

  • 21. Assessment of tumor microenvironment expression and clinical significance of immune inhibitory molecule CTLA-4, ligand B7-1, and tumor-infiltrating regulatory cells in Hodgkin lymphoma.
    Verma RS; Singh G; Singh A; Singh P
    J Med Life; 2023 Apr; 16(4):599-609. PubMed ID: 37305822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy in relapsed classical hodgkin lymphoma.
    Dinner S; Advani R
    J Natl Compr Canc Netw; 2013 Aug; 11(8):968-76. PubMed ID: 23946175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protrusion-guided extracellular vesicles mediate CD30 trans-signalling in the microenvironment of Hodgkin's lymphoma.
    Hansen HP; Engels HM; Dams M; Paes Leme AF; Pauletti BA; Simhadri VL; Dürkop H; Reiners KS; Barnert S; Engert A; Schubert R; Quondamatteo F; Hallek M; Pogge von Strandmann E
    J Pathol; 2014 Mar; 232(4):405-14. PubMed ID: 24659185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment strategy for pediatric Hodgkin lymphoma].
    Koga Y
    Rinsho Ketsueki; 2022; 63(9):1316-1324. PubMed ID: 36198558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphomagenesis in Hodgkin lymphoma.
    Matsuki E; Younes A
    Semin Cancer Biol; 2015 Oct; 34():14-21. PubMed ID: 25725205
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells.
    Weniger MA; Tiacci E; Schneider S; Arnolds J; Rüschenbaum S; Duppach J; Seifert M; Döring C; Hansmann ML; Küppers R
    J Clin Invest; 2018 Jul; 128(7):2996-3007. PubMed ID: 29889102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
    Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
    Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hodgkin lymphoma: Pathology and biology.
    Mathas S; Hartmann S; Küppers R
    Semin Hematol; 2016 Jul; 53(3):139-47. PubMed ID: 27496304
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of a clonally related mantle cell and Hodgkin lymphoma indicates Epstein-Barr virus infection of a Hodgkin/Reed-Sternberg cell precursor in a germinal center.
    Tinguely M; Rosenquist R; Sundström C; Amini RM; Küppers R; Hansmann ML; Bräuninger A
    Am J Surg Pathol; 2003 Nov; 27(11):1483-8. PubMed ID: 14576485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
    Villasboas JC; Ansell S
    Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Not Available].
    Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
    Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ectopic CD137 expression facilitates the escape of Hodgkin and Reed-Sternberg cells from immunosurveillance.
    Pang WL; Ho WT; Schwarz H
    Oncoimmunology; 2013 Apr; 2(4):e23441. PubMed ID: 23734307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Lymphoma-Associated Macrophage to Hodgkin-Reed-Sternberg Cell Ratio Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients.
    Procházka V; Papajík T; Dýšková T; Dihel M; Brychtová S; Prouzová Z; Kriegová E; Lukášová M; Hanáčková V
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):e573-e580. PubMed ID: 31377208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
    Borchmann P; Schnell R; Fuss I; Manzke O; Davis T; Lewis LD; Behnke D; Wickenhauser C; Schiller P; Diehl V; Engert A
    Blood; 2002 Nov; 100(9):3101-7. PubMed ID: 12384405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting macrophages in classical Hodgkin's lymphoma may seem rational, but is it safe?
    Dasanu CA
    J Oncol Pharm Pract; 2012 Mar; 18(1):104-8. PubMed ID: 21248172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Morphological and immunohistochemical investigation of non-Hodgkin's lymphoma combined with Hodgkin's disease.
    Hansmann ML; Fellbaum C; Hui PK; Lennert K
    Histopathology; 1989 Jul; 15(1):35-48. PubMed ID: 2548946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absence of measles virus genome and transcripts in Hodgkin-Reed/Sternberg cells of a cohort of Hodgkin lymphoma patients.
    Maggio E; Benharroch D; Gopas J; Dittmer U; Hansmann ML; Küppers R
    Int J Cancer; 2007 Jul; 121(2):448-53. PubMed ID: 17372912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
    Ansell SM
    Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
    da Costa L; Renner C; Hartmann F; Pfreundschuh M
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma.
    Schwering I; Bräuninger A; Klein U; Jungnickel B; Tinguely M; Diehl V; Hansmann ML; Dalla-Favera R; Rajewsky K; Küppers R
    Blood; 2003 Feb; 101(4):1505-12. PubMed ID: 12393731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.